Khaldoyanidi S, Achtnich M, Hehlmann R, Zöller M
Department of Tumor Progression, and Immune Defense, German Cancer Research Center, Heidelberg, Germany.
Leuk Res. 1996 Oct;20(10):839-51. doi: 10.1016/s0145-2126(96)00048-3.
In a variety of human tumors, including high grade Non-Hodgkin's lymphoma (hgNHL), a linkage between expression of CD44 variant isoforms (CD44v) and tumor progression has been described. In search of an easily accessible diagnostic parameter, expression of CD44 standard (CD44s) and CD44 variant isoforms (exons v5, v6, v7 and v10) in peripheral blood lymphocytes (PBLs) of patients with hematological malignancies was evaluated by fluorescence activated cell scanning. The analysis of 30 blood samples of healthy donors and patients with non-malignant diseases and of 183 blood samples of patients with malignant hematological disorders revealed that only in patients with malignant disorders did a measurable proportion of PBLs express CD44 variant isoforms, mostly exons v5, v6, v7 and, less frequently, exon v10. Elevated levels of CD44v expression were noted in PBLs of patients with acute and chronic myeloid leukemia (AML: 16%, CML: 25%), Hodgkin's disease (HD: 17%), multiple myeloma (MM: 22%), polycythemia vera (PV: 33%), acute lymphoid leukemia (ALL: 23%) and, most frequently, in PBLs of patients with non-Hodgkin's lymphoma (NHL:54%). CD44v expression was not restricted to the malignant phenotype, but instead was also noted in T cells, B cells and monocytes, preferentially in a subpopulation of large cells. Furthermore, expression of CD44v in PBLs was not linked to the histological grading or clinical staging. There was, however, an inverse correlation with tumor progression, whereas response to therapy was frequently accompanied by upregulation of CD44v. Thus, expression of CD44v in the PBLs of patients with NHL mainly reflected immune responsiveness. Since NHL manifests itself primarily in lymphoid organs, its progression is difficult to follow. Monitoring of CD44v in PBLs could be used as an additional and convenient parameter for surveying the course of disease.
在包括高级别非霍奇金淋巴瘤（hgNHL）在内的多种人类肿瘤中，已描述了CD44变异体同工型（CD44v）的表达与肿瘤进展之间的联系。为寻找一种易于获取的诊断参数，通过荧光激活细胞扫描评估了血液系统恶性肿瘤患者外周血淋巴细胞（PBL）中CD44标准型（CD44s）和CD44变异体同工型（外显子v5、v6、v7和v10）的表达。对30份健康供体和非恶性疾病患者的血液样本以及183份恶性血液系统疾病患者的血液样本进行分析后发现，只有恶性疾病患者中有可测量比例的PBL表达CD44变异体同工型，主要是外显子v5、v6、v7，较少见的是外显子v10。在急性和慢性髓细胞白血病（AML：16%，CML：25%）、霍奇金病（HD：17%）、多发性骨髓瘤（MM：22%）、真性红细胞增多症（PV：33%）、急性淋巴细胞白血病（ALL：23%）患者的PBL中，以及最常见的在非霍奇金淋巴瘤（NHL：54%）患者的PBL中，均发现CD44v表达水平升高。CD44v表达不仅限于恶性表型，在T细胞、B细胞和单核细胞中也有发现，且优先出现在大细胞亚群中。此外，PBL中CD44v的表达与组织学分级或临床分期无关。然而，它与肿瘤进展呈负相关，而对治疗的反应常常伴随着CD44v的上调。因此，NHL患者PBL中CD44v的表达主要反映免疫反应性。由于NHL主要在淋巴器官中表现出来，其进展难以追踪。监测PBL中的CD44v可作为一个额外且方便的参数来观察疾病进程。
